Cargando…
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
Duchenne muscular dystrophy (DMD), an incurable and a progressive muscle wasting disease, is caused by the absence of dystrophin protein, leading to recurrent muscle fiber damage during contraction. The inflammatory response to fiber damage is a compelling candidate mechanism for disease exacerbatio...
Autores principales: | Miyatake, Shouta, Shimizu-Motohashi, Yuko, Takeda, Shin’ichi, Aoki, Yoshitsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012616/ https://www.ncbi.nlm.nih.gov/pubmed/27621596 http://dx.doi.org/10.2147/DDDT.S110163 |
Ejemplares similares
-
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019) -
A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
por: Takeshita, Eri, et al.
Publicado: (2018) -
Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019) -
Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021) -
Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2020)